Literature DB >> 10589589

Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.

K A Kern1.   

Abstract

BACKGROUND: Lymphatic mapping in breast cancer performed solely by intraparenchymal injections of blue dye remains an accepted method of identifying sentinel nodes, largely because of its simplicity. As currently practiced, the technique is associated with a marked learning curve, variable identification rates of sentinel nodes, and high false-negative rates. The purpose of this study is to improve dye-only lymphatic mapping of the breast by using an alternative site for injection of blue dye: the subareolar lymphatic plexus. STUDY
DESIGN: In the 10 months between August 1998 and May 1999, 40 women with operable breast cancer in stages I and II underwent lymphatic mapping and sentinel node biopsy performed solely by subareolar injections of blue dye, followed by complete axillary node dissection. The technique involved the injection of 5 mL of 1% isosulfan blue into the subareolar plexus, which consists of breast tissue located immediately beneath the areola. No peritumoral injections of blue dye were performed. The ability of subareolar dye injections to identify sentinel nodes and accurately predict the pathologic status of the axilla was determined and compared with published results for dye-only lymphatic mapping using intraparenchymal injections.
RESULTS: The identification rate of sentinel nodes was 98% (in 39 of 40 patients). Axillary basins harboring positive lymph nodes were found in 15 of these 39 patients (38.5%). Sentinel nodes correctly predicted the status of these 15 positive axillary basins in 100% of the patients. There were no false-negative sentinel node biopsies, indicating a false-negative rate of 0 (in 0 of 15). The overall accuracy, sensitivity, and specificity were 100%.
CONCLUSIONS: Compared with other series of dye-directed lymphatic mapping, the present study of dye-only injections into the subareolar plexus demonstrates a high sentinel node identification rate, absent false-negative rate, and rapid learning curve. On the basis of these findings, we propose that injections into the subareolar lymphatic plexus are the optimal way to perform dye-only lymphatic mapping of the breast.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589589     DOI: 10.1016/s1072-7515(99)00200-8

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  33 in total

Review 1.  Sentinel lymph node mapping for primary breast cancer.

Authors:  Lori L Wilson; Armando E Giuliano
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

2.  Video-assisted breast surgery can sample the second and third sentinel nodes to omit axillary node dissection for sentinel-node-positive patients.

Authors:  K Yamashita; K Shimizu
Journal:  Surg Endosc       Date:  2009-03-05       Impact factor: 4.584

Review 3.  Lymphatics and colorectal liver metastases: the case for sentinel node mapping.

Authors:  Christopher Christophi; Linh Nguyen; Vijayaragavan Muralidharan; Mehrdad Nikfarjam; Jonathan Banting
Journal:  HPB (Oxford)       Date:  2013-07-19       Impact factor: 3.647

4.  Impact of axillary nodal metastases on lymphatic mapping and sentinel lymph node identification rate in patients with early stage breast cancer.

Authors:  Ettore Pelosi; Ada Ala; Marilena Bellò; Anastasios Douroukas; Giuseppe Migliaretti; Ester Berardengo; Teresio Varetto; Riccardo Bussone; Gianni Bisi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-19       Impact factor: 9.236

5.  Comparison of two models for predicting non-sentinel lymph node metastases in sentinel lymph node-positive breast cancer patients.

Authors:  Giovanni D'Eredita'; Vito Leopoldo Troilo; Fernando Fischetti; Giuseppe Rubini; Tommaso Berardi
Journal:  Updates Surg       Date:  2011-05-31

6.  In vivo albumin labeling and lymphatic imaging.

Authors:  Yu Wang; Lixin Lang; Peng Huang; Zhe Wang; Orit Jacobson; Dale O Kiesewetter; Iqbal U Ali; Gaojun Teng; Gang Niu; Xiaoyuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

7.  Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy.

Authors:  J Cantin; H Scarth; M Levine; M Hugi
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

8.  Subareolar subcutaneous injection of blue dye versus peritumoral injection of technetium-labeled human albumin to identify sentinel lymph nodes in breast cancer patients.

Authors:  Roland Reitsamer; Florentia Peintinger; Lukas Rettenbacher; Eva Prokop; Felix Sedlmayer
Journal:  World J Surg       Date:  2003-10-28       Impact factor: 3.352

9.  Subareolar blue dye only injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine.

Authors:  Andreas Kavallaris; Oumar Camara; Ingo B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-20       Impact factor: 4.553

10.  Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer.

Authors:  Gábor Cserni; Mária Rajtár; Gábor Boross; Mária Sinkó; Mihály Svébis; Béla Baltás
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.